A5067372930- Mesenchymal stem cell research
- Biomedical Ethics and Regulation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Spine and Intervertebral Disc Pathology
- Chronic Myeloid Leukemia Treatments
- Medical Imaging and Analysis
- Tissue Engineering and Regenerative Medicine
- Osteoarthritis Treatment and Mechanisms
- Management of metastatic bone disease
- Orthopaedic implants and arthroplasty
- Electrospun Nanofibers in Biomedical Applications
- Bone fractures and treatments
- Cardiovascular Health and Risk Factors
- Periodontal Regeneration and Treatments
- Spinal Cord Injury Research
- Cytomegalovirus and herpesvirus research
- Health Promotion and Cardiovascular Prevention
- Bone and Joint Diseases
- Kruppel-like factors research
- COVID-19 and healthcare impacts
- 3D Printing in Biomedical Research
- Transgenic Plants and Applications
- Urinary and Genital Oncology Studies
- Pericarditis and Cardiac Tamponade
- Spinal Dysraphism and Malformations
Almirall (Spain)
2025
Banc de Sang i Teixits
2013-2024
Genomics England
2024
Genomics (United Kingdom)
2022-2023
Parker Hannifin (United Kingdom)
2020
Basingstoke and North Hampshire Hospital
2012-2013
The aim of the study was to assess real-world feasibility, acceptability, and impact an integrated risk tool for cardiovascular disease (CVD IRT, combining standard QRISK®2 algorithm with a polygenic score), implemented within routine primary practice in UK National Health Service.
<h2>Abstract</h2><h3>Background</h3> Small cardiac tissue engineering constructs show promise for limiting post-infarct sequelae in animal models. This study sought to scale-up a 2-cm<sup>2</sup> preclinical construct into human-size advanced therapy medicinal product (ATMP; PeriCord), and test it first-in-human implantation. <h3>Methods</h3> The PeriCord is clinical-size (12–16 cm<sup>2</sup>) decellularised pericardial matrix colonised with human viable Wharton's jelly-derived mesenchymal...
Introduction: We provide updated long-term safety data for lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). Methods: Integrated from 11 phase 2/3 clinical trials were summarized 2 datasets: 1) All-placebo-controlled Week 0-16 (All-PC; 250 mg every weeks [LEBQ2W] vs placebo); 2) All-LEB (includes patients who received ≥1 dose of any time during the studies). All-PC includes 3 studies ADvocate 1 2, ADhere, ADhere-J, ADopt-VA, ADvantage, 2b KGAF; ADore...
Available information is limited regarding the use of cytoreductive combination therapy in high-risk patients with essential thrombocythemia. This analysis aims to evaluate clinical relevance and patterns treatment European thrombocythemia Evaluation Xagrid® Efficacy Long-term Safety study. Of 3643 patients, 347 (9.5%) received therapy. Data were recorded at each 6-month update. who therapy, 304 (87.6%) hydroxycarbamide + anagrelide. Monotherapies before this (n=167, 54.9%) anagrelide...
Pseudoarthrosis is a relatively frequent complication of fractures, in which the lack mechanical stability and biological stimuli results failure bone union, most frequently humerus tibia. Treatment recalcitrant pseudoarthrosis relies on achievement satisfactory combined with adequate local biology. Herein we present two cases atrophic that received tissue-engineering product (TEP) composed autologous marrow-derived mesenchymal stromal cells (BM-MSC) deantigenized trabecular particles from...
BACKGROUND: The COVID-19 pandemic is placing blood and tissue establishments under unprecedented stress, putting its capacity to provide the adequate care needed at risk. Here we reflect on how our integrated organisational model has faced first impact of describe what challenges, opportunities lessons have emerged. MATERIALS AND METHODS: Catalan Blood Tissue Bank (Banc de Sang i Teixits, BST) described. new scenario was managed by following international recommendations considering in a...
The median age of patients diagnosed with essential thrombocythaemia (ET) is 65–70 years but the management very elderly (aged >80 years) ET has not been well characterized. This study aimed to document treatment patterns in a multinational, real-world setting. EXELS (Evaluation Xagrid Efficacy and Long-term Safety) phase IV observational study, designed monitor efficacy safety cytoreductive therapies clinical practice. In total, 3,598 high-risk were recruited from May 2005 April 2009, 13...
To ascertain the role of patient age as an influencing factor in pharmacokinetics anagrelide and to clarify whether different dosing is required young (18 - 50 years) vs. elderly (≥ 65 patients with essential thrombocythemia (ET).This Phase II, multicenter, open-label study compared pharmacokinetics, pharmacodynamics tolerability its active metabolite, 3-hydroxy-anagrelide, ET. Three days prior pharmacokinetic assessment, divided their normal daily into a structured twice-daily (BID)...
Background There are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, virally safe biological material, rich in tissue factors. Materials methods We aimed validate bioprocess design the production blood-derived concentrates (CBPC) public Cord Blood Bank (CBB). CBPC was defined product 10±5 mL, 1,000±200×109/L total platelets, free erythrocytes...
A systematic and ordered product development program, in compliance with current quality regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal (ATMP) for clinical use as safe effective therapy. As this is novel field, little accurate information available regarding steps to be followed, produced support an ATMP. Notably, translation can somewhat cumbersome academic researchers. In article, we have provided summary information, supported by our...
Background Gonarthrosis is the most common cause of pain and disability in middle-aged elderly people [1,2]. The lack long-lasting effective treatments for repairing degenerated articular cartilage has spurred research into novel cell-based therapies aiming at reducing pain, slowing degeneration and, ultimately, reverting natural history osteoarthritis (OA) [3]. Herein we report development a mesenchymal stromal cell (MSC)-based therapy, from conception up to completion Phase I/IIa...
(1) Background: the use of Mesenchymal Stromal Cells (MSC) in emerging therapies for spinal cord injury (SCI) hold potential to improve functional recovery. However, development cell-based medicines is challenging and preclinical studies addressing quality, safety efficacy must be conducted prior clinical testing; (2) Methods: herein we present (i) characterization quality attributes MSC from Wharton's jelly (WJ) umbilical cord, (ii) intrathecal infusion a 3-month subchronic toxicity...